Biogen (BIIB) Current Deferred Revenue (2010 - 2012)

Biogen has reported Current Deferred Revenue for 3 years, with the latest figure at $110.3 million in Q2 2012.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $110.3 million in Q2 2012; TTM through Jun 2012 was $110.3 million, a N/A change from a year earlier, with the FY2011 full-year figure at $69.6 million, up 68.52% from the prior year.
• Current Deferred Revenue was $110.3 million for Q2 2012 at Biogen, up from $96.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $110.3 million in Q2 2012, with the low at $41.3 million in Q4 2010.
• Average Current Deferred Revenue over 3 years is $79.3 million, with a median of $82.8 million recorded in 2011.
• The largest YoY upside for Current Deferred Revenue was 68.52% in 2011 against a maximum downside of 68.52% in 2011.
• Over 3 years, Current Deferred Revenue stood at $41.3 million in 2010, then surged by 68.52% to $69.6 million in 2011, then soared by 58.48% to $110.3 million in 2012.
• The last three Current Deferred Revenue figures came in at $110.3 million (Q2 2012), $96.0 million (Q1 2012), and $69.6 million (Q4 2011), per Business Quant data.